Jeffrey G. Gross
VANCOUVER, British Columbia — The 5-year outcomes from the DRCR.net Protocol S study support the use of either ranibizumab or panretinal photocoagulation for the treatment of proliferative diabetic retinopathy, according to a speaker here.
“These findings support either ranibizumab or PRP as viable treatment for proliferative diabetic retinopathy. Patient-specific factors should be considered,” Jeffrey G. Gross, MD, said at the American Society of Retina Specialists annual meeting.
The previously published 2-year outcomes for the study showed the mean change in
Uncategorized